Stockscreener 앱 받기
17.55
4.20%
-0.77
Tenax Therapeutics Inc 주식(TENX)의 최신 뉴스
FMR LLC reports 3.94M-share holding in Tenax Therapeutics (TENX) - Stock Titan
Tenax Therapeutics: 'Hold' TNX-103 Data August 2026But With Caution Ahead (NASDAQ:TENX) - Seeking Alpha
LifeSci Capital Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Raises Target Price to $35 - Moomoo
Price to sales forward of Tenax Therapeutics, Inc. – NASDAQ:TENX - TradingView
Tenax lures three new hires with 160,000 stock options - Stock Titan
Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026 - Investing News Network
(TENX) Risk Channels and Responsive Allocation - Stock Traders Daily
Tenax Therapeutics Is Maintained at Buy by Chardan Capital - Moomoo
Tenax Therapeutics to Present Phase 3 LEVEL Trial Results for Levosimendan in PH-HFpEF at ESC Congress 2026 - Minichart
Tenax Therapeutics Price Target Maintained With a $27.00/Share by Chardan Capital - Moomoo
Tenax Therapeutics highlights key Phase 3 LEVEL trial - TipRanks
Late-breaking ESC 2026 spot for Tenax (TENX) Phase 3 LEVEL trial data - Stock Titan
Tenax Therapeutics to present Phase 3 trial results at ESC By Investing.com - Investing.com Australia
Tenax Therapeutics to present Phase 3 trial results at ESC - Investing.com
Tenax and Orion Secure Long-Term Levosimendan Supply Deal - The Globe and Mail
TENX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Sharp Stock RallyAnalyst Drop Coverage - dars.gov.et
Tenax Therapeutics Extends Us Regulatory Approval Deadline To December 31, 2035 Via Sixth Amendment To Orion LicenseSEC Filing - TradingView
Tenax Therapeutics, Inc. has extended the deadline for U.S. regulatory approval to December 31, 2035, through the sixth amendment to its licensing agreement with Orion. - Bitget
Tenax Therapeutics (NASDAQ: TENX) deepens Orion deal, extends approval deadline to 2035 - Stock Titan
Tenax Therapeutics Updates Executive and Employee Severance Protections - TipRanks
Tenax Therapeutics (TENX) expands executive and employee severance, CIC plans - Stock Titan
Tenax Therapeutics, Inc.(NasdaqCM: TENX) added to Russell 2000 Index - marketscreener.com
Tenax Therapeutics, Inc.(NasdaqCM: TENX) added to Russell 2000 Value Benchmark - marketscreener.com
Tenax Therapeutics, Inc.(NasdaqCM:TENX) added to Russell Microcap Value Benchmark Index - marketscreener.com
Tenax Therapeutics, Inc.(NasdaqCM: TENX) added to Russell 3000E Index - marketscreener.com
Tenax Therapeutics, Inc.(NasdaqCM: TENX) added to Russell 2000 Dynamic Index - marketscreener.com
Tenax Therapeutics, Inc.(NasdaqCM: TENX) added to Russell Microcap Index - marketscreener.com
Tenax Therapeutics, Inc. Actuals & Estimates (NASDAQ:TENX) - TradingView
Tenax Therapeutics, Inc. Actuals & Estimates (FWB:YBO0) - TradingView
Tenax Therapeutics, Inc. Actuals & Estimates (BOATS:TENX) - TradingView
TENX Forecast — Price Target — Prediction for 2027 - TradingView
TENX Reiterates by Cantor Fitzgerald -- Price Target Maintained at $35.00 - GuruFocus
Here's Why We're Not Too Worried About Tenax Therapeutics' (NASDAQ:TENX) Cash Burn Situation - Moomoo
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX), Abbott Laboratories (ABT) and AbbVie (ABBV) - The Globe and Mail
TENX Maintained by Guggenheim -- Price Target Raised to $40 - GuruFocus
TENX Initiated Coverage by Chardan Capital -- Rating Set as Buy - GuruFocus
Guggenheim raises Tenax Therapeutics stock price target on trial confidence By Investing.com - Investing.com Nigeria
Tenax Therapeutics Is Maintained at Buy by Guggenheim - Moomoo
Guggenheim raises Tenax Therapeutics stock price target on trial confidence - Investing.com
(TENX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Tenax Therapeutics (TENX) Edges Higher at $12.0: Testing Key Resistance in Biotech SectorRetail Volume - dars.gov.et
Tenax Therapeutics Inc (TENX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tenax Therapeutics Inc (TENX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tenax Therapeutics Inc (TENX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tenax Therapeutics Inc (TENX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tenax Therapeutics Inc (TENX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tenax Therapeutics Inc (TENX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tenax Therapeutics (TENX) Surges 4.8% as Momentum Builds Above Key SupportEarnings Quality Factor - newsline.com
Tenax Therapeutics Inc (TENX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tenax Therapeutics Inc (TENX) Institutional Confidence - TradingKey
TENX Maintained by Piper Sandler -- Price Target Raised to $50 - GuruFocus
Tenax Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesEarnings Season Outlook - newsline.com
Tenax Therapeutics Price Target Raised to $50.00/Share From $20.00 by Piper Sandler - Moomoo
Piper Sandler raises Tenax Therapeutics price target on trial data By Investing.com - Investing.com Canada
Tenax Therapeutics (TENX) Slips 3.25% as Stock Tests Key Support LevelsMerger Arbitrage - newsline.com
T. Rowe Price discloses 586,990 Tenax shares (NASDAQ: TENX) in amended 13G - Stock Titan
What's Driving Tenax Therapeutics' Recent Surge - Kavout
2.64%
자본화:
|
볼륨(24시간):